NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$4.6b

Last Updated

2021/05/15 22:16 UTC

Data Sources

Company Financials +

Executive Summary

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Intellia Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NTLA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: NTLA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-1.0%

NTLA

-0.4%

US Biotechs

-1.7%

US Market


1 Year Return

279.6%

NTLA

19.7%

US Biotechs

50.8%

US Market

Return vs Industry: NTLA exceeded the US Biotechs industry which returned 19.2% over the past year.

Return vs Market: NTLA exceeded the US Market which returned 50.5% over the past year.


Shareholder returns

NTLAIndustryMarket
7 Day-1.0%-0.4%-1.7%
30 Day-10.3%-0.3%-1.2%
90 Day-1.8%-10.3%0.4%
1 Year279.6%279.6%21.5%19.7%53.3%50.8%
3 Year169.9%169.9%24.5%18.1%61.5%51.4%
5 Year147.0%147.0%49.5%38.0%125.9%100.7%

Long-Term Price Volatility Vs. Market

How volatile is Intellia Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Intellia Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NTLA ($67.04) is trading below our estimate of fair value ($150.86)

Significantly Below Fair Value: NTLA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NTLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: NTLA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NTLA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NTLA is overvalued based on its PB Ratio (8.3x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

27.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NTLA's revenue (63% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: NTLA's revenue (63% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NTLA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Intellia Therapeutics performed over the past 5 years?

-30.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NTLA is currently unprofitable.

Growing Profit Margin: NTLA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NTLA is unprofitable, and losses have increased over the past 5 years at a rate of 30.7% per year.

Accelerating Growth: Unable to compare NTLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).


Return on Equity

High ROE: NTLA has a negative Return on Equity (-27.23%), as it is currently unprofitable.


Financial Health

How is Intellia Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: NTLA's short term assets ($601.1M) exceed its short term liabilities ($60.7M).

Long Term Liabilities: NTLA's short term assets ($601.1M) exceed its long term liabilities ($110.3M).


Debt to Equity History and Analysis

Debt Level: NTLA is debt free.

Reducing Debt: NTLA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NTLA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NTLA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 32% each year


Dividend

What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTLA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NTLA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

John Leonard (63 yo)

3.33yrs

Tenure

US$3,635,676

Compensation

Dr. John M. Leonard, M.D., is an Executive Partner at Tyree & D'Angelo Partners. He has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Le...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD3.64M) is below average for companies of similar size in the US market ($USD5.35M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NTLA's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: NTLA's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.6%.


Top Shareholders

Company Information

Intellia Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intellia Therapeutics, Inc.
  • Ticker: NTLA
  • Exchange: NasdaqGM
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.569b
  • Shares outstanding: 68.15m
  • Website: https://www.intelliatx.com

Number of Employees


Location

  • Intellia Therapeutics, Inc.
  • 40 Erie Street
  • Suite 130
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Biography

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRIS...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 22:16
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.